Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
47.92%
Operating Margin
58.83%
Net Margin
48.40%
Efficiency Metrics
Revenue per Expense Ratio
3.05
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
85.08%
Income Tax Rate
7.77%
EPS
10.0900000000
Balance Sheet Analysis
Current Ratio
1.32
Cash Ratio
0.02
Working Capital
$123.65M
Debt to Equity
0.90
Debt to Assets
40.93%
Equity Ratio
45.66%
Cash Flow Analysis
Operating Cash Flow Ratio
62.05%
Free Cash Flow Ratio
-34.71%
CapEx to Revenue
96.76%
Dividends Paid
$123.95M
Stock Buybacks
$8.00M
Total Shareholder Returns
$131.95M
Cash Position Change
224.17%
Key Takeaways (2023 FY)
Revenue declined by 3.967624098725%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 45.27%
Detailed Growth Metrics
Core Performance
Revenue
-3.97%
Net Income
19.36%
EPS
8.96%
Operating Income
31.49%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-22.88%
Operating Cash Flow
27.46%
Free Cash Flow
-53.45%
Balance Sheet Health
Assets
55.96%
Debt
20.33%
Book Value per Share
135.94%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
45.27%
Shares Outstanding
16.45%
Long Term Trends
3Y Revenue/Share
174.95%
5Y Revenue/Share
-0.31%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%